Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > I cannot get the smile of my face even when sleeping !
View:
Post by Oden6570 on Dec 02, 2021 3:24am

I cannot get the smile of my face even when sleeping !

Coombs received a Sponsored Research Contract from Theralase Biotechnologies, Inc., a Toronto-based company that specializes in photodynamic compounds and their use against pathogenic organisms and cancer. Theralase had previously determined one of their compounds was effective against bacteria and cancers at doses that are not toxic to normal human cells, and we were contracted to determine if the compound also is effective against viruses, including coronaviruses. This research, assisted by two of Coombs’ graduate students, Kathleen Glover and Mahamud Rashid, has determined that low-nanomolar concentrations of the Theralase compound can kill influenza virus, Zika virus and human coronaviruses within seconds. Thus, the compound may represent a very rapid and very safe alternative to standard methods that are used to prepare inactivated virus vaccines, and may also be useful as a therapeutic for individuals who cannot receive normal vaccines.
Comment by VerusSemperSors on Dec 02, 2021 6:05am
What are you quoting? I would like to read the whole thing. -TIA!
Comment by Oden6570 on Dec 02, 2021 6:38am
Here you go however  below  is more detailed as to the full story ! University of Manitoba - Faculty of Medicine - Medical Microbiology and Infectious Diseases - MMID CoVID-19 Research (umanitoba.ca) Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine V.TLT | April 9, 2021  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250